X4 Pharmaceuticals (XFOR) Depreciation & Amortization (CF) (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Depreciation & Amortization (CF) for 10 consecutive years, with $997000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) rose 180.85% year-over-year to $997000.0; the trailing twelve-month figure through Jun 2026 stood at $1.7 million (up 21.52% YoY), and the FY2025 full-year result was $1.3 million, up 60.43% from the prior year.
• Depreciation & Amortization (CF) climbed to $997000.0 in Q2 2026 per XFOR's latest filing, from $223000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $997000.0 in Q2 2026 and bottomed at $62000.0 in Q4 2023.
• Historically, Depreciation & Amortization (CF) has averaged $234722.2 across 5 years, with a median of $163500.0 in 2022.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) soared 667.74% in 2025, then plunged 53.15% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $124000.0 in 2022, then plunged by 50.0% to $62000.0 in 2023, then surged by 340.32% to $273000.0 in 2024, then fell by 18.32% to $223000.0 in 2025, then surged by 347.09% to $997000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $997000.0, $223000.0, and $223000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.